Mankind Pharma Q4 Revenue Up 11.8%, EBITDA Margin 27.1%

Mankind Pharma reported Q4FY26 revenue of ₹3,443 Cr, up 11.8% YoY, with adjusted EBITDA margin expanding 400 bps to 27.1%.
Domestic business grew 13.4% driven by strong performance in cardiac (14.7%) and anti-diabetes (11.6%) therapies, while OTC grew 20%.
Full-year FY26 revenue reached ₹14,278 Cr, up 17.0% YoY, with exports growing 34.5% despite Q4 geopolitical headwinds limiting growth to 4.2%.
The company maintained its #1 rank in domestic prescriptions with 15.1% market share and highlighted progress in chronic portfolio expansion to ~40% share.